

ISV ANNUAL CONGRESS 2026 — ORAL PROGRAM			
MONDAY, 12 OCTOBER 2026			
08:00-10:00	REGISTRATION		Room
09:00-10:00	WELCOME COFFEE		Room
10:00-10:10	OPENING SESSION		
	WELCOME BY ISV PRESIDENT: Manon Cox , <i>NextWaveBio, USA</i> CO-CHAIR REMARKS: Michael Schotsaert , <i>Icahn School of Medicine at Mount Sinai, USA</i> Lakshmi Krishnan , <i>National Research Council (NRC), Canada</i> Isabel Leroux-Roels , <i>University of Ghent, Belgium</i>		Room
10:10-10:55	STANLEY PLOTKIN LECTURE		
	Yellow fever 17D live attenuated vaccine: A great vaccine but how does it work? Alan Barrett , <i>The University of Texas Medical Branch (UTMB), USA</i>		Room
10:55-11:45	PLENARY SESSION 1: Population Impact of Vaccination		Room
	Session Chairs: TBC		Room
10:55-11:20	Clinical Data for the RSVpreF Vaccine in Older Adults, At-Risk Adults Aged 18-59, and Immunocompromised Adults Kumar Ilangoan , <i>Pfizer Vaccine R & D, USA</i>		Room
11:20-11:45	Rotavirus Vaccines: Where We Are and What's Next Michelle Groome , <i>University of Witwatersrand, South Africa</i>		Room
11:45-12:15	KEYNOTE SPEAKER		
	From Preclinical Insight to Clinical Evidence: Advancing the Next Generation of Pneumococcal Conjugate Vaccines Annaliesa Anderson , <i>Pfizer, USA</i>		Room
12:15-13:30	LUNCH		Room
12:30-13:30	SANOFI WORKSHOP		Room
13:30-15:05	PLENARY SESSION 2: Mucosal Vaccines		Room
	Session Chairs: TBC		Room
13:30-13:55	New Insights Into Receptor Usage by Orthoflaviviruses Michael S. Diamond , <i>Washington University School of Medicine, USA</i>		Room
13:55-14:20	Adjuvants - The Tool to Obtain the Required Immune Responses in Vaccination Dennis Christensen , <i>CRODA Pharma, Denmark</i>		Room
14:20-14:35	Charting Mucosal Immune Responses to Influenza using Human Immune-competent Organoids Martin Beukema , <i>University Medical Center Groningen, The Netherlands</i>		Room
14:35-14:50	Environmental drivers of oral typhoid vaccine responses in Uganda: dissecting rural–urban differences and the role of Schistosoma mansoni Bridgious Walusimbi , <i>MRC/UVRI and LSHTM Uganda Research Unit, Uganda</i>		Room
14:50-15:05	Inhaled aerosol vaccination with an adenoviral-vectored TB vaccine induces robust respiratory mucosal immunity in humans Sam Afkhami , <i>McMaster University, Canada</i>		Room
15:05-15:30	COFFEE BREAK		Room
15:30-17:35	CONCURRENT SESSION 1	CONCURRENT SESSION 2	CONCURRENT SESSION 3
	(Room)	(Room)	(Room)
	Adjuvants	Vaccine Regulatory Science and Policy	“Bright Sparks” in Vaccinology
	Session Chairs: TBC	Session Chairs: TBC	PhD Student Session
			Session Chairs: TBC

15:30-15:55	Open-access Adjuvants for Prophylactic Human Vaccines Marcelle Van Mechelen, <i>Vaccine Formulation Institute, Switzerland</i>	Regulatory Acceptance of Immunological Biomarkers as Surrogate for Vaccine Efficacy – Ebola Zaire Vaccine Case Marie-Chantal Uwamwezi, <i>PATH, Belgium</i>	Cross-Reactive SARS-CoV-2 Antibodies in Pre-Pandemic Gambian Sera Exhibit Fc-Mediated Effector Activity Dawda Jobe, <i>MRC Unit The Gambia at LSHTM (15:30-15:40)</i> Seroepidemiology and serum bactericidal activity of IgG antibodies to Non Typhoidal Salmonella in healthy Children in Mukuru informal settlement in Kenya Schola Kamwethya, <i>Kenya Medical Research Institute, Kenya (15:40-15:50)</i> Switchover Break (15:50-15:55)	
15:55-16:20	From Empirical Adjuvants to Programmable Immunity Nathalie Garcon, <i>n3j consulting, Belgium</i>	Beyond Efficacy — Economic Intelligence Across the Vaccine Development Pipeline Beate Sander, <i>University of Toronto, Canada</i>	The Effect of Malaria Intermittent Preventive Treatment on Vaccine Responses and SARS-CoV-2 Seroprevalence in Adolescents: Findings from a Randomised Controlled Trial Ludoviko Zirimenya, <i>MRC/UVRI & LSHTM Uganda Research Unit, Uganda (15:55-16:05)</i> APC-Mimetic Dendritic Cell-Derived Extracellular Vesicle Nanovaccine with STING Adjuvant Induces Long-Term Th1 Immunity and Immune Memory Against Dengue Virus Anindita Sengupta, <i>Indian Institute of Technology, India (16:05-16:15)</i> Switchover Break (16:15-16:20)	
16:20-16:35	Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1 Giang Dang Chu, <i>Chonnam National University</i>	Primary Healthcare Surveillance and Vaccination Challenges During the 2025 Meningococcal Serogroup C Outbreak Response in Sokoto State, Northern Nigeria Ikechukwu Nnaji, <i>Nigeria Centre for Disease Control and Prevention (NCDC), Nigeria</i>	Induction of influenza-specific immunity in pigs using dissolvable microneedle patches to deliver an adenovirus-based vaccine Inés Co Rives, <i>University College Cork, Ireland</i> Includes 5 minute Switchover Break	
16:35-16:50	Modulation of the bone marrow hematopoietic and immune cell landscape by vaccine adjuvants Eleanor Burgess, <i>Icahn School of Medicine</i>	Speaker + Affiliation	Systemic response and short-term functional changes following infection with <i>Necator americanus</i> third-stage infective larvae: Insights from a control human hookworm infection trial in Lambarene, Gabon Therese Vanessa Amana Bokagne, Centre de Recherches Medicales de Lambarene, Gabonese Republic Includes 5 minute Switchover Break	
16:50-17:05	Neutrophils are the dominant early responders to a potent liposomal vaccine adjuvant Lee Sims, <i>University of Oxford, United Kingdom</i>	Speaker + Affiliation	Intranasal protein-based vaccines protect against 2.3.4.4b H5N1 infection in young and old BALB/C mice Gabriel Laghali, <i>Icahn School of Medicine at Mount Sinai, USA</i> Includes 5 minute Switchover Break	
17:05-17:20	Speaker + Affiliation	PANEL DISCUSSION	A simplified and sensitive assay for tracking virus-specific T cell responses in the nasal cavity during SARS-CoV-2 human challenge studies Previtha Dawn Sakthi Vale, <i>National University of Singapore, Singapore</i> Includes 5 minute Switchover Break	
17:20-17:35	Speaker + Affiliation		AI-Driven Infodemic Surveillance and Its Impact on COVID-19 Vaccine Uptake in Sub-Saharan Africa: A Multi-Country Study Angyiba Serge Andigema, <i>Department of Research, Bisons' Scholars, Douala, Cameroon</i>	
17:35-19:00	POSTER SESSION 1			Room
18:00-20:00	WELCOME RECEPTION			Room

ISV ANNUAL CONGRESS 2026 — ORAL PROGRAM			
TUESDAY, 13 OCTOBER 2026			
08:00-08:30	WELCOME COFFEE		Room
08:30-09:00	KEYNOTE SPEAKER		
	Microbiota Control of Host Immunity Yasmine Belkaid , <i>Institut Pasteur, France</i>		Room
09:00-10:30	PLENARY SESSION 3: Vaccine Technology		Room
	Session Chairs: TBC		Room
09:00-09:25	Beyond the needle - discussing the future of vaccine technologies Tarit Mukhopadhyay , <i>Merck, USA</i>		Room
09:25-09:50	Advancing Therapeutic Vaccines Through Clinically Validated LNP Delivery Technologies Xiangrong Song , <i>WestGene Biopharma, China</i>		Room
09:50-10:15	TITLE TBC Emilio Fumero , <i>Moderna, Spain</i>		Room
10:15-10:30	Safety, Reactogenicity and Immunogenicity of a Launch-iT Rabies Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study in Healthy Adults Joke Debruyn , <i>Astrivax Therapeutics, Belgium</i>		Room
10:30-11:00	KEYNOTE SPEAKER		
	Entering the Vaccine Space During Uncertain Times Peter Marks , <i>Eli Lilly and Company, USA</i>		Room
11:00-11:30	COFFEE BREAK		Room
11:00-12:35	CONCURRENT SESSION 4 (Room)	CONCURRENT SESSION 5 (Room)	CONCURRENT SESSION 6 (Room)
	Immunotherapies Session Chairs: TBC	Vaccines for vector-borne diseases Session Chairs: TBC	“Bright Sparks” in Vaccinology ECR Session
11:00-11:25	Unleashing our innate immune system as defense against disease Joost Kreijtz , <i>Trained Therapeutix Discovery (TTxD)</i> , Netherlands	From Efficacy to Impact: What We Can Learn About Dengue Vaccination From TAK-003, a Tetravalent Dengue Vaccine Liudmyla Budovska , <i>Takeda Pharmaceuticals International AG, Switzerland</i>	Effectiveness of PCV10 and PCV13 against invasive pneumonia disease in vietnamese children prior to national introduction: a matched case-control study Cong Hieu Truong , <i>Pasteur Institute in Ho Chi Minh City, Vietnam</i> (11:00-11:10)
			Age-specific immunity gaps and residual susceptibility to measles and rubella before and after the measles–rubella supplementary immunisation campaign in South India Ramya Madhavan , <i>Christian Medical College, India</i> (11:10-11:20) Switchover Break (11:20-11:25)
11:25-11:50	Antibody effector functions in antiviral immunity Taia Wang , <i>Stanford University School of Medicine, USA</i>	Controlled human infection studies to accelerate vaccine development Meta Roestenberg , <i>Leiden University, Netherlands</i>	Antigen composition, not T-cell functionality, limits cross-reactivity to distant Coronaviruses after bivalent SARS2 Spike vaccination Ziyin Wang , <i>La Jolla Institute for Immunology, USA</i> (11:25-11:35)
			Implementation Effectiveness of a Community-Driven Vaccination Model at Boosting Immunization in Two Conflict-Affected Health Districts of Cameroon: A Quasi-Experimental Study Derrick Nebangwa , <i>Community-Driven Vaccination Programme (CoVACC), Cameroon</i> (11:35-11:45) Switchover Break

			(11:45-11:50)
11:50-12:05	In situ cancer immunotherapy with modified MVdeltaC measles virus induces potent RIG-I-dependent tumor clearance and immune memory Frederic Tangy , <i>Institut Pasteur Oncovita, France</i>	Structural Basis of 4G2-Induced Antibody-Dependent Enhancement in Flaviviruses Camilla Di Giulio , <i>Global Health Institute, EPFL, Switzerland</i>	Establishing a blood-stage Controlled Human Malaria Infection model in healthy Tanzanian adults with varying prior exposure to P. falciparum Omar Hassan , <i>Ifakara Health Institute, Tanzania</i> <i>Includes 5 minute Switchover Break</i>
12:05-12:20	Therapeutic HBV vaccine efficacy through ancestral mismatched T cell epitopes Antonio Bertoletti , <i>Duke-NUS Medical School, Singapore</i>	Rational design of live-attenuated West Nile virus vaccines that are non-transmissible by vector mosquitoes Gorben Pijlman , <i>Wageningen University & Research, The Netherlands</i>	An Intranasal Hemagglutinin Protein Booster After Intramuscular mRNA Vaccination Enhances Mucosal Immunity and Confers Protection Against Influenza Virus in Ferrets Seokchan Park, Icahn School of Medicine at Mount Sinai, USA <i>Includes 5 minute Switchover Break</i>
12:20-12:35	mRNA-Encoded HSV Monoclonal Antibody Based Immunotherapy Outperforms Acyclovir in a Murine Model of HSV-1 Encephalitis Sita Awasthi , <i>University of Pennsylvania, USA</i>	Novel dengue virus non-structural protein vaccine that can prevent disease exacerbation caused by existing vaccines Kyoko Tsukiyama-Kohara , <i>Kagoshima University, Japan</i>	Divergent innate and humoral immune responses to 4CMenB vaccination in transgender individuals receiving gender-affirming hormone therapy Anthony Willems , <i>Ghent University, Belgium</i> <i>Includes 5 minute Switchover Break</i>
12:35-14:00	LUNCH		Room
13:00-14:00	NRC WORKSHOP		Room
14:00-15:30	POSTER SESSION 2		Room
14:30-15:30	ISV ANNUAL GENERAL MEETING		Room
15:30-16:00	COFFEE BREAK		Room
16:00-17:35	PLENARY SESSION 4: Systems Vaccinology		Room
	Session Chairs: TBC		Room
16:00-16:25	Complexity from Simplicity: Using Systems Immunology to Define Conserved Innate Immune Mechanisms Mediating Diverse Effector Responses to Vaccines Jeffrey Tomalka , <i>Emory University, USA</i>		Room
16:25-16:50	TITLE TBC Fernando Ulloa-Montoya , <i>Sanofi, France</i>		Room
16:50-17:05	Induction of HIV broadly neutralizing antibodies by human vaccination Isabel Baken , <i>Amsterdam UMC, The Netherlands</i>		Room
17:05-17:20	Genome-guided identification and validation of novel T-cell vaccine targets for cross-species malaria protection Carla Proietti , <i>The University of Queensland, Australia</i>		Room
17:20-17:35	Novel DNA Delivery Method Using Lipid Nanoparticles Induces Durable Polyfunctional Immune Responses with Tier2 Neutralizing Antibody and Cytotoxic CD8 T Cells Barbara Felber , <i>NCI/NIH, USA</i>		Room
17:35-17:50	Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates Ji Ma , <i>The First Affiliated Hospital (Southwest Hospital) of Army Medical University, People's Republic of China</i>		Room
18:30-22:00	GALA DINNER		Room

ISV ANNUAL CONGRESS 2026 — ORAL PROGRAM			
WEDNESDAY, 14 OCTOBER 2026			
08:00-08:30	WELCOME COFFEE		Room
08:30-09:00	KEYNOTE SPEAKER		
	From Global Partnerships to Local Impact: Strengthening Vaccine Innovation Laura Palomares , <i>Instituto de Biotecnología UNAM</i>		Room
09:00-10:30	PLENARY SESSION 5: One Health and Pandemic Preparedness		
	Session Chairs: TBC		Room
09:00-09:25	Active and Passive Mucosal Immunization Strategies for Improved Pandemic Preparedness Matthew Miller , <i>McMaster University, Canada</i>		Room
09:25-09:50	Antigenic evolution of H5 viruses and subtype-wide H5 vaccine development Mathilde Richard , <i>Erasmus MC, Netherlands</i>		Room
9:50-10:05	Safety of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in Tanzanian adults: an open-label, non-randomised phase 1 clinical trial Latipha Mohamed , <i>Ifakara Health Institute, Tanzani</i>		Room
10:05-10:20	Single-visit rabies vaccination with a simian adenovirus vector elicits durable neutralising antibody responses indicating likely protection for >2 years: mid-term results from the RAB002 phase Ib/II clinical trial Alexander Douglas , <i>University of Oxford, United Kingdom</i>		Room
10:20-10:35	Design, Development and Characterisation of Multivalent mRNA-LNP Vaccine Candidates for Mpox Hapiloe Maranyane-Tshililo , <i>Afrigen Biologics & Vaccines, South Africa</i>		Room
10:35-11:00	COFFEE BREAK		Room
11:00-12:35	CONCURRENT SESSION 7	CONCURRENT SESSION 8	CONCURRENT SESSION 9
	(Room)	(Room)	(Room)
	Vaccine Confidence	Emerging Infections	Veterinary Vaccines
	Session Chairs: TBC	Session Chairs: TBC	Session Chairs: TBC
11:00-11:25	The State of Vaccine Confidence in 2026 Emilie Karafillakis , <i>London Institute for Tropical Medicine and Hygiene, United Kingdom</i>	TBC	TBC
11:25-11:50	Beyond Vaccine Hesitancy: Understanding and Rebuilding Trust in Vaccination in Complex Social Ecosystems Ève Dubé , <i>Laval University, Canada</i>	TITLE TBC Raman Rao , <i>Hilleman Labs, Singapore</i>	Gamma-SU: A serotype independent Strep. suis vaccine Tim Hirst , <i>GPN Vaccines, Australia</i>
11:50-12:05	Bridging the Mpox Vaccine Uptake Gap in Africa: Determinants of Acceptance and Hesitancy from a Systematic Review and Meta-Analysis Charles Ibeneme , <i>Texila America University Zambia Campus, Zambia</i>	Stabilized henipavirus fusion glycoproteins induce strong serum neutralizing antibody responses against of authentic virus and inform future vaccine design. Haye Nijhuis , <i>Amsterdam UMC, The Netherlands</i>	Selection and characterization of a contemporary respiratory syncytial virus subtype B strain for use in Controlled Human Infection Model (CHIM) studies Albert Osterhaus , <i>University of Veterinary Medicine, Germany</i>
12:05-12:20	PANEL DISCUSSION	CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infection Lara Kelchtermans , <i>KU Leuven, Belgium</i>	Development of a vaccine against deadly elephant endotheliotropic herpesvirus Xander De Haan , <i>Utrecht University, The Netherlands</i>
12:20-12:35	PANEL DISCUSSION	Characterization of the immune response to <i>Fusobacterium nucleatum</i> , an emerging pathogen associated with adverse pregnancy outcomes Tracy Lee , <i>BC Cancer Research Institute</i>	Speaker + Affiliation
12:35-14:00	LUNCH		Room
13:00-14:00	CAREER DEVELOPMENT WORKSHOP		Room
14:00-14:30	AWARD CEREMONY		Room

14:30-14:55	ISV PAPER OF THE YEAR	
	A natural experiment on the effect of herpes zoster vaccination on dementia Pascal Gladsetzer , <i>Stanford University, USA</i>	Room
14:55-16:10	PLENARY SESSION 6: Human Challenge Studies	Room
	Session Chairs: TBC	Room
14:55-15:20	TITLE TBC Joren Raymenants , <i>University of Antwerp, Belgium</i>	Room
15:20-15:45	TBC	Room
15:45-16:00	CLOSING SESSION & INTRODUCTION TO 2027 ISV CONGRESS	